2025
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
2006
Unprotected intercourse for extra money among commercial sex workers in Kinshasa, Democratic Republic of Congo
Ntumbanzondo M, Dubrow R, Niccolai L, Mwandagalirwa K, Merson M. Unprotected intercourse for extra money among commercial sex workers in Kinshasa, Democratic Republic of Congo. AIDS Care 2006, 18: 777-785. PMID: 16971288, DOI: 10.1080/09540120500412824.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply